Abstract:Abstract The interleukin-4/13 receptor antagonist dupilumab dramatically changed the landscape of eczema treatment following NICE approval in 2018, and many patients now achieve remission or significant symptomatic improvement without notable side-effects. This has led to a rapid uptake in use; our department has > 300 patients with eczema currently taking dupilumab. However, cutaneous T-cell lymphoma (CTCL) can mimic eczema and may respond to conventional systemic therapies; an unproven relationship with dupilumab exists (Park A, Wong L, Lang A et al. Cutaneous T-cell lymphoma following dupilumab use: a systematic review. Int J Dermatol 2023; 62: 962–76). Between 2019 and 2022, five dupilumab-treated patients with ‘eczema’ at our centre were found to have CTCL: three Sézary syndrome (one now deceased) and two atypical CTCL. Whether they had pre-existing CTCL or dupilumab had altered their phenotype was unknown; two of our patients with Sézary syndrome had lifelong eczema. We therefore introduced peripheral blood flow cytometric evaluation as part of our routine dupilumab examinations and 4 months after starting treatment. Furthermore, any patient with atypical eczema received a biopsy prior to starting dupilumab. From June to December 2023, 55 patients (29 female) from our complex eczema clinic started dupilumab. The mean age was 41 years (range 19–90). In total, 62% had atopy, 62% had a family history of eczema and 76% had had eczema since childhood. At baseline, 29% had abnormal peripheral blood flows, but none had Sézary syndrome. Abnormal findings included elevated and reduced CD4 : CD8 ratios (7% and 5%, respectively). Two had clonal changes. So far, in patients with a normal flow completing 4 months of treatment, 50% had normal levels when retested. Abnormal repeat flows in this group included reversed or elevated CD4 : CD8 ratio and new non-Sézary clonal change. Of patients with an abnormal baseline flow, 75% remained static when retested on treatment. One patient’s abnormal clonal population had changed phenotype. Nine patients with atypical eczema had pre-dupilumab biopsies, but none showed features of CTCL. Of the five previously identified patients with CTCL on dupilumab, one responded well to dupilumab and four did not respond. The two patients without Sézary syndrome were both biopsied 1–2 years prior to starting dupilumab, with no suggestion of CTCL. We advocate further investigation including biopsy and flow cytometry in atypical cases prior to dupilumab initiation, as dupilumab can cause CTCL progression in later stages. Flow cytometry is not typically carried out on patients with inflammatory disease, and almost one-third of our patients had an abnormal flow. Prescribers must remain vigilant for unrecognized severe side-effects with new medications. It is reassuring that we have not identified any cases of CTCL from our baseline screening so far, but we cannot exclude the possibility of CTCL developing after starting dupilumab, and we are continuing to monitor these patients.

The changes of leukocytes and T lymphocytes in atopic dermatitis patients with and without dupilumab therapy and in control group in pollen season compared to out of pollen season

The differences in the count of B lymphocytes in atopic dermatitis patients with and without dupilumab therapy and in healthy subjects in pollen season and out of pollen season

Differences in immunological profile in atopic dermatitis patients with and without dupilumab therapy

The expression of CD200 and CD23 on B lymphocytes in the pollen season and outside the pollen season in atopic dermatitis patients with and without dupilumab therapy

The association between expression of CD200 on B lymphocytes and the count of eosinophils and basophils in atopic dermatitis patients with and without dupilumab therapy – Pilot study

The interaction between NK cells and ILC cells and their subsets in atopic dermatitis patients with and without dupilumab therapy

Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: an Analysis of a Randomized, Double-Blind Phase III Study

Evaluation of innate lymphoid cells and their subsets in atopic dermatitis patients with and without dupilumab therapy

Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab

Histological features of immune cell infiltrate in lesional skin correlate with therapeutic response to dupilumab

Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis

Characterization of Inflammatory Mediators and Metabolome in Interstitial Fluid Collected with Dermal Open Flow Microperfusion before and at the End of Dupilumab Treatment in Atopic Dermatitis

The Changes of IgE Levels in Type 2 Inflammatory Diseases after Treatment of Dupilumab: a Systematic Review and Meta-Analysis

Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab

Peripheral blood mononuclear cell- transcriptome signatures of atopic dermatitis and prediction for the efficacy of dupilumab

Dupilumab and House Dust Mite Immunotherapy in Patients with Atopic Dermatitis: A Preliminary Study

Evolution of pathologic B-cell subsets and serum environment-specific sIgEs in patients with atopic dermatitis and controls, from infancy to adulthood

Exploring the Potential of IL-4 and IL-13 Plasma Levels as Biomarkers in Atopic Dermatitis

P037 Peripheral blood flow cytometry reveals heterogeneous but benign T-cell changes in patients with severe eczema undergoing dupilumab therapy